214 related articles for article (PubMed ID: 36276141)
1. Transcriptome profile and clinical characterization of ICOS expression in gliomas.
Wang J; Shi F; Shan A
Front Oncol; 2022; 12():946967. PubMed ID: 36276141
[TBL] [Abstract][Full Text] [Related]
2. Molecular and clinical characterization of ANG expression in gliomas and its association with tumor-related immune response.
Wang J; Shan A; Shi F; Zheng Q
Front Med (Lausanne); 2023; 10():1044402. PubMed ID: 37928479
[TBL] [Abstract][Full Text] [Related]
3. Molecular and Clinical Characterization of LIGHT/TNFSF14 Expression at Transcriptional Level
Yang Y; Lv W; Xu S; Shi F; Shan A; Wang J
Front Mol Biosci; 2021; 8():567327. PubMed ID: 34513918
[TBL] [Abstract][Full Text] [Related]
4. Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma.
Wang Z; Zhang C; Liu X; Wang Z; Sun L; Li G; Liang J; Hu H; Liu Y; Zhang W; Jiang T
Oncoimmunology; 2016; 5(11):e1196310. PubMed ID: 27999734
[No Abstract] [Full Text] [Related]
5. MELK is a prognostic biomarker and correlated with immune infiltration in glioma.
Yang H; Zhou H; Wang G; Tian L; Li H; Zhang Y; Xue X
Front Neurol; 2022; 13():977180. PubMed ID: 36353126
[TBL] [Abstract][Full Text] [Related]
6. Molecular and clinical characterization of PTPN2 expression from RNA-seq data of 996 brain gliomas.
Wang PF; Cai HQ; Zhang CB; Li YM; Liu X; Wan JH; Jiang T; Li SW; Yan CX
J Neuroinflammation; 2018 May; 15(1):145. PubMed ID: 29764444
[TBL] [Abstract][Full Text] [Related]
7. CHI3L2 Is a Novel Prognostic Biomarker and Correlated With Immune Infiltrates in Gliomas.
Liu L; Yang Y; Duan H; He J; Sun L; Hu W; Zeng J
Front Oncol; 2021; 11():611038. PubMed ID: 33937022
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive Analysis of PD-1 Gene Expression, Immune Characteristics and Prognostic Significance in 1396 Glioma Patients.
Liu C; Zhang Z; Ping Y; Qin G; Zhang K; Maimela NR; Huang L; Yang S; Zhang Y
Cancer Manag Res; 2020; 12():4399-4410. PubMed ID: 32606935
[TBL] [Abstract][Full Text] [Related]
9. PD-L2 expression is correlated with the molecular and clinical features of glioma, and acts as an unfavorable prognostic factor.
Wang ZL; Li GZ; Wang QW; Bao ZS; Wang Z; Zhang CB; Jiang T
Oncoimmunology; 2019; 8(2):e1541535. PubMed ID: 30713802
[No Abstract] [Full Text] [Related]
10. CD96, a new immune checkpoint, correlates with immune profile and clinical outcome of glioma.
Liu F; Huang J; He F; Ma X; Fan F; Meng M; Zhuo Y; Zhang L
Sci Rep; 2020 Jul; 10(1):10768. PubMed ID: 32612110
[TBL] [Abstract][Full Text] [Related]
11. PD-1 related transcriptome profile and clinical outcome in diffuse gliomas.
Liu S; Wang Z; Wang Y; Fan X; Zhang C; Ma W; Qiu X; Jiang T
Oncoimmunology; 2018; 7(2):e1382792. PubMed ID: 29308304
[No Abstract] [Full Text] [Related]
12. miR-17-5p-CXCL14 axis related transcriptome profile and clinical outcome in diffuse gliomas.
Zeng A; Yin J; Wang Z; Zhang C; Li R; Zhang Z; Yan W; You Y
Oncoimmunology; 2018; 7(12):e1510277. PubMed ID: 30524906
[TBL] [Abstract][Full Text] [Related]
13. Genetic and clinical characterization of B7-H3 (CD276) expression and epigenetic regulation in diffuse brain glioma.
Wang Z; Wang Z; Zhang C; Liu X; Li G; Liu S; Sun L; Liang J; Hu H; Liu Y; Zhang W; Jiang T
Cancer Sci; 2018 Sep; 109(9):2697-2705. PubMed ID: 30027617
[TBL] [Abstract][Full Text] [Related]
14. Correlation of immune phenotype with IDH mutation in diffuse glioma.
Berghoff AS; Kiesel B; Widhalm G; Wilhelm D; Rajky O; Kurscheid S; Kresl P; Wöhrer A; Marosi C; Hegi ME; Preusser M
Neuro Oncol; 2017 Oct; 19(11):1460-1468. PubMed ID: 28531337
[TBL] [Abstract][Full Text] [Related]
15. Large-scale analysis reveals the specific clinical and immune features of B7-H3 in glioma.
Zhang C; Zhang Z; Li F; Shen Z; Qiao Y; Li L; Liu S; Song M; Zhao X; Ren F; He Q; Yang B; Fan R; Zhang Y
Oncoimmunology; 2018; 7(11):e1461304. PubMed ID: 30377558
[No Abstract] [Full Text] [Related]
16. MET overexpression contributes to STAT4-PD-L1 signaling activation associated with tumor-associated, macrophages-mediated immunosuppression in primary glioblastomas.
Wang QW; Sun LH; Zhang Y; Wang Z; Zhao Z; Wang ZL; Wang KY; Li GZ; Xu JB; Ren CY; Ma WP; Wang HJ; Li SW; Zhu YJ; Jiang T; Bao ZS
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34667077
[TBL] [Abstract][Full Text] [Related]
17. Identification of integrative molecular and clinical profiles of Fibrinogen-like protein 2 in gliomas using 1323 samples.
Song Z; Wang Y; Du Y; Zhang Z; Yuan Y
Int Immunopharmacol; 2020 Nov; 88():106894. PubMed ID: 32858440
[TBL] [Abstract][Full Text] [Related]
18. CTSB is a negative prognostic biomarker and therapeutic target associated with immune cells infiltration and immunosuppression in gliomas.
Ma K; Chen X; Liu W; Chen S; Yang C; Yang J
Sci Rep; 2022 Mar; 12(1):4295. PubMed ID: 35277559
[TBL] [Abstract][Full Text] [Related]
19. S100A10 Is a New Prognostic Biomarker Related to the Malignant Molecular Features and Immunosuppression Process of Adult Gliomas.
Ma K; Chen S; Chen X; Yang C; Yang J
World Neurosurg; 2022 Sep; 165():e650-e663. PubMed ID: 35779750
[TBL] [Abstract][Full Text] [Related]
20. DDOST Correlated with Malignancies and Immune Microenvironment in Gliomas.
Chang X; Pan J; Zhao R; Yan T; Wang X; Guo C; Yang Y; Wang G
Front Immunol; 2022; 13():917014. PubMed ID: 35812432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
